IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis characterized by the deposition of IgA in the glomerular mesangium, leading to a spectrum of histopathological lesions and a variable clinical course that can progress to end-stage renal disease in a significant proportion of patients.
Vilya raises $21M in Series A extension; Shionogi to build research center in San Diego
Plus, news about Immutep, Eisai and Iterum Therapeutics: Computational biotech extends Series A: Vilya Therapeutics, a startup based in Seattle, Sign up to read this